KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Novartis Ag (NVS) Short term Debt (2017 - 2025)

Novartis Ag (NVS) has disclosed Short term Debt for 9 consecutive years, with $794.0 million as the latest value for Q4 2025.

  • Quarterly Short term Debt rose 23.68% to $794.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $794.0 million through Dec 2025, up 23.68% year-over-year, with the annual reading at $794.0 million for FY2025, 23.68% up from the prior year.
  • Short term Debt hit $794.0 million in Q4 2025 for Novartis Ag, up from $642.0 million in the prior quarter.
  • In the past five years, Short term Debt ranged from a high of $6.3 billion in Q4 2021 to a low of $624.0 million in Q4 2023.
  • Historically, Short term Debt has averaged $2.9 billion across 5 years, with a median of $794.0 million in 2025.
  • Biggest five-year swings in Short term Debt: skyrocketed 177.07% in 2021 and later plummeted 89.48% in 2023.
  • Year by year, Short term Debt stood at $6.3 billion in 2021, then fell by 5.78% to $5.9 billion in 2022, then tumbled by 89.48% to $624.0 million in 2023, then increased by 2.88% to $642.0 million in 2024, then rose by 23.68% to $794.0 million in 2025.
  • Business Quant data shows Short term Debt for NVS at $794.0 million in Q4 2025, $642.0 million in Q4 2024, and $624.0 million in Q4 2023.